Related Experiment Videos

A selective inducible NOS dimerization inhibitor prevents systemic, cardiac, and pulmonary hemodynamic dysfunction in

Fumito Ichinose1, Ryuji Hataishi, Justina C Wu

  • 1Department of Anesthesia and Critical Care and Cardiovascular Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114-2620, USA. ichinose@etherdome.mgh.harvard.edu

Insights

Selective inhibition of inducible nitric oxide synthase (NOS2) dimerization with BBS-2 prevents sepsis-induced cardiovascular dysfunction, including hypotension and myocardial impairment in mice.

Area of Science:

  • Cardiovascular Physiology
  • Sepsis Pathophysiology
  • Pharmacology

Background:

  • Increased nitric oxide (NO) production by inducible NO synthase (NOS2) contributes to cardiovascular complications in sepsis.
  • NOS2 functions as an obligate homodimer, presenting a potential therapeutic target.

Purpose of the Study:

  • To evaluate the efficacy of a selective NOS2 dimerization inhibitor, BBS-2, in preventing endotoxin-induced cardiovascular dysfunction in a mouse model.
  • To assess the impact of BBS-2 on systemic hypotension, myocardial dysfunction, and impaired hypoxic pulmonary vasoconstriction (HPV).

Main Methods:

  • Mice were challenged with Escherichia coli endotoxin and subsequently treated with BBS-2 or vehicle.
  • Hemodynamic parameters, echocardiographic measures of myocardial function, and HPV responses were assessed.
  • Plasma nitrate and nitrite levels were measured to confirm NOS2 inhibition.

Main Results:

  • BBS-2 treatment effectively blocked NOS2 dimerization and inhibited endotoxin-induced increases in plasma nitrate and nitrite.
  • BBS-2 administration prevented systemic hypotension and attenuated myocardial dysfunction in endotoxemic mice.
  • BBS-2 treatment also preserved HPV function, which was impaired by endotoxin.

Conclusions:

  • Selective inhibition of NOS2 dimerization with BBS-2 effectively mitigates key cardiovascular sequelae of sepsis in mice.
  • This targeted approach, sparing other NOS isoforms, represents a promising therapeutic strategy for sepsis treatment.

Related Concept Videos